GlucoTrack (GCTK) Stock Price, News & Analysis

Company Overview

GlucoTrack, Inc. (NASDAQ:GCTK) is a medical-device company focused on developing glucose-monitoring technologies for people with diabetes. The company’s work is aimed at providing alternatives to conventional blood-glucose testing and commercially available continuous glucose-monitoring systems.

GlucoTrack’s earlier product was the GlucoTrack device, a noninvasive glucose-monitoring system designed to estimate glucose levels through a sensor attached to the earlobe. The company has also been developing an implantable continuous blood glucose monitoring system intended to provide ongoing glucose measurements over an extended period. These technologies remain subject to applicable regulatory review and commercialization requirements.

The company was originally established in Israel under the name Integrity Applications and later adopted the GlucoTrack name. Its activities have included product development and regulatory efforts in international markets, with a particular focus on diabetes-care applications. GlucoTrack is a development-stage medical technology company, and the availability and approval status of its products may vary by geography.

Key Stats

• Today's Range: $0.30 to $0.37
• 50-Day Range: $0.30 to $7.36
• 52-Week Range: $0.28 to $207.00
• Volume: 28,504 shs
• Average Volume: 707,506 shs
• Market Capitalization: $378.88 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

GlucoTrack Stock Analysis - MarketRank™

GlucoTrack scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

GlucoTrack has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

GlucoTrack has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of GlucoTrack is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GlucoTrack is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GlucoTrack has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.99% of the float of GlucoTrack has been sold short.

Short Interest Ratio / Days to Cover

GlucoTrack has a short interest ratio ("days to cover") of 0.55, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GlucoTrack has recently increased by 18.53%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GlucoTrack does not currently pay a dividend.

Dividend Growth

GlucoTrack does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

GlucoTrack has a news sentiment score of -0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for GlucoTrack this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for GCTK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added GlucoTrack to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GlucoTrack insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.90% of the stock of GlucoTrack is held by insiders.

Percentage Held by Institutions

10.92% of the stock of GlucoTrack is held by institutions.

Company Calendar

• Today: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:GCTK
• CIK: 1506983
• Web: www.glucotrack.com
• Phone: +97286757878
• Fax: 972-8675-7850
• Employees: 15
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($275.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.39 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2,135.52%
• Return on Assets: -290.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.46
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $83.85 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 1,184,000
• Free Float: 1,114,000
• Market Cap: $378.88 thousand
• Optionable: Not Optionable
• Beta: 0.90